AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00617500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flower therapy
Description: Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
Study NCT00617500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
Study NCT00617500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular therapy
Description: Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
Study NCT00617500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormones
Description: Estradiol 1 mg and a drospirenone 2mg/day (3 months)
Study NCT04502485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric water exchange
Description: Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further.
Study NCT04502485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional air insufflation
Description: Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
Study NCT04320732 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observation of behavior and COVID-19 infection will be conducted.
Description: No intervention, only prospective observation of behavior will be conducted by a questionnaire.
Study NCT04597983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2S-hesperidin
Description: Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
Study NCT04597983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
Study NCT02445807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06-Cream
Description: Twice daily topical application for 14 days.
Study NCT02445807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Twice daily topical application for 14 days.
Study NCT01531309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178
Description: AGO178 is administered as a sublingual tablet.
Study NCT02199938 — intervention group
Intervention type: OTHER
Intervention: Identification and characterization of molecular markers in musculoskeletal tumors
Study NCT00113828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant
Description: Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant.
Study NCT00113828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell depleted peripheral blood stem cell transplant
Description: Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant .
Study NCT01643629 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate (HPL)
Description: Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
Study NCT01643629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2 % Minoxidil and /or Finasteride
Description: Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
Study NCT00400673 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Two-step remission induction and risk-oriented consolidation
Study NCT02261194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Tools
Study NCT04342000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement education workshop
Description: 30 minutes total:~* 10 minutes sedentary activity (LE injury risk factor and anatomy instruction)~* 10 minutes moderate activity (guided discovery of body segment alignment and stability with squat, lunge, plank, jump, and hop technique assessment and corrective feedback)~* 10 minutes vigorous activity (practical application of body segment alignment and stability including hopping, jumping, and running activities with technique assessment and corrective feedback)~For the month following the athlete workshop, prior to the final assessment, subjects will receive periodic text message instructions. These messages will include key facts and takeaways from the workshop, and reminders about correct form.
Study NCT04342000 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Education Workshop
Description: 30 minutes total:~* 10 minute sedentary activity (sleep, nutrition, and hydration instruction)~* 10 minutes moderate activity (performance of squat, lunge, plank, jump, and hop activities - no technique assessment or corrective feedback)~* 10 minutes vigorous activity (hopping, jumping, and running activities - no technique assessment and corrective feedback)
Study NCT02216032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMW Curriculum
Study NCT02216032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Curriculum
Study NCT00885274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pico-Salax
Description: Both doses of Pico-Salax taken the evening prior to colonoscopy
Study NCT00885274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split Dose Pico-Salax
Description: One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
Study NCT02620696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: netazepide
Study NCT03729063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twice-daily expired carbon monoxide (CO) measurements
Description: Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
Study NCT03729063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal control
Description: Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
Study NCT00450723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan blue
Description: Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
Study NCT00450723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Axillary Lymph Node Dissection
Study NCT01326949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
Study NCT01326949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ET+NSBB
Description: ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0).
Study NCT00450723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
Study NCT00450723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Sentinel Lymph Node Biopsy
Study NCT00450723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic Surgery
Description: Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
Study NCT00450723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99m Sulfur Colloid
Description: Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
Study NCT01669161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivistim System
Description: The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
Study NCT01669161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehab Only
Description: Rehabilitation without device implant and VNS
Study NCT03762369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-351
Description: twice a day
Study NCT03762369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: once a day
Study NCT03762369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D930
Description: three times a day
Study NCT03762369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D930
Description: three times a day
Study NCT03762369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of CKD-351
Description: once a day
Study NCT03762369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of CKD-351
Description: twice a day
Study NCT03762369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of D930
Description: three times a day
Study NCT04700839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Description: Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
Study NCT04700839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
Study NCT00977236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Description: Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
Study NCT00977236 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single-vision spectacle lenses
Description: Daily use of spectacles to correct the refractive error for a period of two years
Study NCT03300999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger tea
Description: 1. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle.
Study NCT03215771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoPro Motion-G
Description: The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
Study NCT03215771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning-Based Therapy
Description: Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
Study NCT00554567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing and Care Services
Description: Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
Study NCT03978195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive device for middle ear ventilation
Description: Daily use of the device
Study NCT03737383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: brief, trauma-focused treatment.
Study NCT00772486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISF35
Description: Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
Study NCT02754895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Psychology (PP)
Description: Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
Study NCT02754895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session.
Study NCT02441465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
Study NCT02441465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Labeled Vemurafenib
Description: IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters \[mL\], which corresponds to a dose of 20 micrograms \[mcg\] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
Study NCT04784728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Description: lidocaine patch
Study NCT04442945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX3-71
Description: Active oral dose of ANAVEX3-71
Study NCT04442945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT04444999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide Angiography
Description: • Automated carbon dioxide angiography: Patients are placed in the Trendelenburg position with the feet elevated of 10 º degrees. Carbon Dioxide automatic injection will be performed by digital Angiodroid injection system
Study NCT00787462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
Study NCT00787462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
Study NCT02076997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.
Study NCT01187186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT00732277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
Study NCT01787682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOOST High Protein
Study NCT01737476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation. PFC
Study NCT01737476 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation. PFC
Study NCT00652366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, escalating dose
Description: 100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
Study NCT00652366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib, standard dose
Description: 100mg, PO, once daily
Study NCT00652366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
Study NCT00652366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
Study NCT00889265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CopiOs Pericardium Membrane
Description: CopiOs Pericardium, Puros Cancellous
Study NCT04535349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-body & CZT bone tracer imaging (SPECT)
Description: Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
Study NCT03034564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Northera
Study NCT03034564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT00867399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-126
Description: See arm for details
Study NCT03061032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir 12W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
Study NCT03061032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir plus Ribavirin 12W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.